Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: GOG 0280 Principal Investigator: Mutch, David
Title: A Phase II Evaluation of the Potent, Highly Selective Poly (ADP-RIBOSE) Polymerase (PARP) -1 and -2 Inhibitor Veliparib (ABT-888) (IND #77840) (NSC #737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation
Phase: II Disease Site: Multiple Sites
Participating Site(s):
 
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
You are being asked to take part in this study because you have ovarian, fallopian tube or primary peritoneal cancer, you carry a germline BRCA1 or BRCA 2 mutation, and your cancer has regrown or not responded after prior treatment.

The purpose of this study is to find out if the investigational drug, Veliparib (ABT-888), works in treating your type of cancer and to find out what side effects are caused by treatment with this drug. Veliparib (ABT-888) inhibits the enzyme Poly ADP ribose polymerase (PARP). Drugs such as ABT-888 are commonly called “PARP inhibitors.” Veliparib (ABT-888) and other PARP inhibitors have been tested in some patients with ovarian cancer. Many of these studies included women who carry a germline mutation in BRCA1 or BRCA2. The BRCA1 and BRCA2 genes code for proteins that help to repair DNA damage. About 10% of ovarian cancer patients have an inherited defect in the BRCA1 or the BRCA2 genes. These patients were included because it is believed that their tumors are particularly sensitive to PARP blockade. In these studies, recurrent tumors have reduced in size in some women suggesting that PARP inhibitors may be of value in this setting.
 
More Information:
Internal Protocol Documents (requires Siteman administrative database password)